Exclusivity vs. Patents - Pharmaceutical Executive


Exclusivity vs. Patents
A new pathway for follow-on biologics relies on data exclusivity to shield innovators from early competition

Pharmaceutical Executive

An interesting provision in the Senate bill calls for the government to determine how much money the healthcare system saves by allowing FOBs to come to market. The Department of the Treasury will study the market and establish a Biological Product Savings Fund to channel those savings to other public health programs. A lot of interest groups have predicted huge gains from FOBs, and it will be interesting to see the results.

Jill Wechsler is Pharmaceutical Executive's Washington correspondent. She can be reached at


blog comments powered by Disqus

Source: Pharmaceutical Executive,
Click here